JERUSALEM, Israel, October 15, 2025 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, announced today that it raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund. Existing shareholders Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited demonstrated strong confidence in Omnix’s approach by taking part in the round alongside new external investors, including Prevail Partners and OurCrowd.

Read more here.